Endo Inc

Thank you for standing by. Welcome to the earnings conference call for Endo, Inc. This call is being recorded. If you have any objections, you may disconnect at this time. I would now like to turn the call over to Lori Park, Senior Vice President, Investor Relations and Corporate Affairs. You may begin.

Good morning, and thank you for joining us to discuss Endo, Inc.' 's second quarter 2024 financial results. Joining me on today's call is Paul Herendine, the Chairman of Endo's Board. Mark Bradley, Executive Vice President and CFO, and Patrick Berry, Executive Vice President and President, Global Commercial Operations. We have prepared a slide presentation to accompany today's webcast, and that full presentation, as well as other materials, are posted online in the Investor section at endo.com. Additionally, later this morning, a copy of our prepared comments will also be posted online in the Investor section at endo.com. I would like to remind you that any forward-looking statements made by management on today's call are covered under the U.S. Private Securities Litigation Reform Act of 1995 and are subject to significant changes, risks, and uncertainties described in our earnings release and other press releases and in our SEC filings. Actual results may differ materially from those set forth in any forward-looking statements. Substantially, all of Endo International's assets were acquired by Endo, Inc. on April 23, 2024, pursuant to Endo International's plan of reorganization. The combined second quarter financial results presented today reflect the effects of the plan of reorganization and the application of Fresh Start Accounting. For clarification, during this call, all references to second quarter 2024 results refer to combined Endo, Inc. and Endo International PLC results. All references to second quarter 2023 results refer to Endo International PLC results. A complete discussion of the impact of the accounting adjustments related to the transactions contemplated in the plan of reorganization, which became effective on April 23, 2024, the application of Fresh Start accounting in accordance with accounting standards codification number 852, and related disclosures will be found in our Form 10Q to be filed in the coming days. In addition, during the course of today's call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and may differ from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8K, furnished with the SEC, for ENDO's reasons for including those non-GAAP financial measures in its earnings release and presentation. The reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are contained in our earnings release issued earlier this morning and less otherwise noted. I would now like to turn the call over to Paul.

Thank you, Lori. I'll add my good morning to everyone and thank you for joining us. This morning, we announced that the board is starting a search for Endo's next CEO and that Scott Hirsch, another of Endo's directors, has been appointed interim CEO. On behalf of the board, I want to thank Blaise Coleman for his many contributions to Endo. We appreciate his successful leadership of the company during very challenging times, and we wish him all the best. As a board, we believe there are significant opportunities on the horizon for Endo. With our restructuring complete, the company is free from legacy overhangs and ready to enter its next phase. We sit here today with a clean balance sheet, modest leverage, a diversified portfolio, we're returning to growth, we're generating cash, and now we have the opportunity to deploy that cash for future growth. The decision to transition to a new CEO at this time was to tailor leadership to our emerging growth opportunities. We'll be looking for a leader with the experience, skill set, and strategic vision to help us leverage our capabilities and pursue additional strategies to drive long-term value for stakeholders. The board will work with purpose to identify and appoint the best candidate to lead the company forward. In the near term, we're confident that Scott is the right person to lead Endo through this transition. He brings deep operating and industry experience and is committed to advancing our mission. Scott was the CEO of Solta Medical, where he led a growing global business through an expansion cycle. Prior to that, he was the Chief Business Officer and President of the Orthodermatologics and Oral Pharma business segments at Bausch Health. I worked closely with Scott during his time at Bausch and can personally attest to his ability to adapt to situations quickly, make sound decisions, and keep his eye on the prize. We're all grateful that he has agreed to step in and lead Endo while the search is ongoing. With that, I'll turn the call over to Mark for a review of our financial results.